0000000000075707

AUTHOR

Paolo Grossi

showing 10 related works from this author

Ceftazidime-avibactam use for klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: A retrospective observational multicenter study

2021

Abstract Background A growing body of observational evidence supports the value of ceftazidime-avibactam (CAZ-AVI) in managing infections caused by carbapenem-resistant Enterobacteriaceae. Methods We retrospectively analyzed observational data on use and outcomes of CAZ-AVI therapy for infections caused by Klebsiella pneumoniae carbapenemase–producing K. pneumoniae (KPC-Kp) strains. Multivariate regression analysis was used to identify variables independently associated with 30-day mortality. Results were adjusted for propensity score for receipt of CAZ-AVI combination regimens versus CAZ-AVI monotherapy. Results The cohort comprised 577 adults with bloodstream infections (n = 391) or nonba…

Microbiology (medical)Adultmedicine.medical_specialtyAzabicyclo CompoundcarbapenemasesBacterial ProteinMicrobial Sensitivity TestsNeutropeniaCeftazidimebeta-Lactamasesbeta-LactamaseCarbapenemasecarbapenemaseBacterial ProteinsRetrospective StudieLower respiratory tract infectionInternal medicineDrug CombinationAnti-Bacterial AgentmedicineHumansKPC-producing Klebsiella pneumoniaeRetrospective StudiesSeptic shockbusiness.industryCeftazidime-avibactamMicrobial Sensitivity Testceftazidime-avibactamMortality rateCarbapenemases; Ceftazidime-avibactam; KPC-producing Klebsiella pneumoniae; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeKPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactammedicine.diseaseCeftazidime/avibactamSettore MED/17KPC-producing Klebsiella pneumoniae; carbapenemases; ceftazidime-avibactam; Adult; Anti-Bacterial Agents; Azabicyclo Compounds; Bacterial Proteins; Ceftazidime; Drug Combinations; Humans; Microbial Sensitivity Tests; Retrospective Studies; beta-Lactamases; Klebsiella Infections; Klebsiella pneumoniaeAnti-Bacterial AgentsKlebsiella InfectionsDrug CombinationsKlebsiella pneumoniaeInfectious DiseasesCohortPropensity score matchingObservational studybusinessAzabicyclo Compoundsmedicine.drugHumanKlebsiella Infection
researchProduct

Zygomycosis in Italy: A survey of FIMUA-ECMM (Federazione Italiana di Micopatologia Umana ed Animale and European Confederation of Medical Mycology)

2009

Abstract The aims of the study were to analyze the clinical and epidemiological characteristics and treatments for patients who developed zygomycosis enrolled in Italy during the European Confederation of Medical Mycology of medical mycology survey. This prospective multicenter study was performed between 2004 and 2007 at 49 italian Departments. 60 cases of zygomycosis were enrolled: the median age was 59.5 years (range 1-87), with a prevalence of males (70%). The majority of cases were immunocompromised patients (42 cases, 70%), mainly hematological malignancies (37). Among non-immunocompromised (18 cases, 30%), the main category was represented by patients with penetrating trauma (7/18, 3…

AdultMalemedicine.medical_specialtyAdolescentEpidemiologyAntifungal drugImmunocompromised HostPharmacotherapyZygomycosisDrug Resistance FungalAmphotericin BInternal medicineEpidemiologymedicineHumansPharmacology (medical)ChildMycosisAgedPharmacologyImmunocompromised hostAged 80 and overbusiness.industryMortality rateMucormycosisInfantEpidemiology; Immunocompromised host; ZygomycosisMiddle Agedmedicine.diseaseSurgeryInfectious DiseasesOncologyItalyChild PreschoolFemaleZygomycosisbusinessmedicine.drug
researchProduct

Voriconazole and squamous cell carcinoma after lung transplantation: A multicenter study

2017

This study evaluated the independent contribution of voriconazole to the development of squamous cell carcinoma (SCC) in lung transplant recipients, by attempting to account for important confounding factors, particularly immunosuppression. This international, multicenter, retrospective, cohort study included adult patients who underwent lung transplantation during 2005-2008. Cox regression analysis was used to assess the effects of voriconazole and other azoles, analyzed as time-dependent variables, on the risk of developing biopsy-confirmed SCC. Nine hundred lung transplant recipients were included. Median follow-up time from transplantation to end of follow-up was 3.51 years. In a Cox re…

Lung DiseasesMaleOncologylung diseaseAntifungal AgentsSkin Neoplasmsmedicine.medical_treatment030230 surgeryTHERAPY030207 dermatology & venereal diseases0302 clinical medicinelung transplantation/pulmonologypatient safetyEPIDEMIOLOGYMedicineImmunology and AllergyPharmacology (medical)malignant [complication]RISKHazard ratioImmunosuppressionMiddle AgedPrognosisinfection and infectious agents - fungalPRACTICE GUIDELINEScomplication: malignantCarcinoma Squamous Cellantifungal [antibiotic]FemaleLung Transplantationmedicine.drugCohort studyAdultmedicine.medical_specialtyAdolescentinfectious diseaseSOCIETYANTIFUNGAL PROPHYLAXISclinical research/practiceArticleYoung Adult03 medical and health sciencesantibiotic: antifungal; clinical research/practice; complication: malignant; health services and outcomes research; infection and infectious agents - fungal; infectious disease; lung disease; lung transplantation/pulmonology; patient safety; Immunology and Allergy; Transplantation; Pharmacology (medical)LONG-TERM VORICONAZOLEInternal medicineHumansLung transplantationEXPOSUREAgedRetrospective StudiesVoriconazoleTransplantationSKIN-CANCERbusiness.industryProportional hazards modelRetrospective cohort studyantibiotic: antifungalhealth services and outcomes researchTransplant RecipientsSurgeryTransplantationRECIPIENTSVoriconazolebusinessFollow-Up Studies
researchProduct

The 2015 International Society for Heart and Lung Transplantation Guidelines for the management of fungal infections in mechanical circulatory suppor…

2016

Shahid Husain, MD, MS, Amparo Sole, MD, PhD, Barbara D. Alexander, MD, MHS, Saima Aslam, MD, MS, Robin Avery, MD, Christian Benden, MD, Eliane M. Billaud, PharmD, PhD, Daniel Chambers, MBBS, MD, Lara Danziger-Isakov, MD, Savitri Fedson, MD, Kate Gould, MD, Aric Gregson, MD, Paolo Grossi, MD, PhD, Denis Hadjiliadis, MD, Peter Hopkins, MD, Me-Linh Luong, MD, Debbie J.E. Marriott, MD, Victor Monforte, MD, Patricia Munoz, MD, PhD, Alessandro C. Pasqualotto, MD, PhD, Antonio Roman, MD, Fernanda P. Silveira, MD, Jeffrey Teuteberg, MD, MS, Stephen Weigt, MD, Aimee K. Zaas, MD, MHS, Andreas Zuckerman, MD, and Orla Morrissey, MD, PhD

Adult0301 basic medicinePulmonary and Respiratory Medicinemedicine.medical_specialty2747 TransplantationHeart-Lung Transplantation030106 microbiology610 Medicine & health030230 surgery2705 Cardiology and Cardiovascular Medicine03 medical and health sciencesPostoperative Complications0302 clinical medicinePrevalencemedicineHumansAssisted CirculationChildTransplantationbusiness.industryIncidence2746 SurgerySurgeryMycoses2740 Pulmonary and Respiratory MedicineAdult; Child; Humans; Incidence; Mycoses; Postoperative Complications; Prevalence; Assisted Circulation; Heart-Lung Transplantation; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular Medicine; TransplantationSurgery10178 Clinic for PneumologyCardiology and Cardiovascular MedicinebusinessHumanitiesThe Journal of Heart and Lung Transplantation
researchProduct

A challenging case of chorioretinitis and skin lesions in a lung transplant recipient

2018

no

infection and infectious agentsmedicine.medical_specialtyinfectious diseaseclinical research/practicecomplication: infectioulung transplantation/pulmonologyBiopsymedicineImmunology and AllergybiopsyPharmacology (medical)Lung transplant recipientTransplantationmedicine.diagnostic_testinfection and infectious agentbusiness.industryChorioretinitisantibiotic: antifungalmedicine.diseaseinfection and infectious agents - fungalDermatologycomplication: infectiousAntibiotics antifungalInfectious disease (medical specialty)Skin lesionbusinessantibiotic: antifungal; biopsy; clinical research/practice; complication: infectious; infection and infectious agents; infection and infectious agents - fungal; infectious disease; lung transplantation/pulmonology; Immunology and Allergy; Transplantation; Pharmacology (medical)American Journal of Transplantation
researchProduct

Lack of association of Aspergillus colonization with the development of bronchiolitis obliterans syndrome in lung transplant recipients: An internati…

2019

BACKGROUND: Bronchiolitis obliterans syndrome (BOS) is a major limitation in the long-term survival of lung transplant recipients (LTRs). However, the risk factors in the development of BOS remain undetermined. We conducted an international cohort study of LTRs to assess whether Aspergillus colonization with large or small conidia is a risk factor for the development of BOS.METHODS: Consecutive LTRs from January 2005 to December 2008 were evaluated. Rates of BOS and associated risk factors were recorded at 4 years. International Society of Heart and Lung Transplantation criteria were used to define fungal and other infections. A Cox proportional-hazards-model was constructed to assess the a…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAdolescentInternational Cooperationmedicine.medical_treatmentBronchiolitis obliterans030230 surgeryCohort StudiesYoung Adult03 medical and health sciencesPostoperative Complications0302 clinical medicineRisk FactorsInternal medicinemedicineHumansLung transplantationBOSCumulative incidenceRisk factorBronchiolitis ObliteransTransplantationbusiness.industryHazard ratioMiddle Agedcolonizationmedicine.diseasehumanitiesBOS; aspergillus; colonization; lung transplantation; risk factorsTransplantationAspergillus030228 respiratory systemCohortFemaleSurgeryCardiology and Cardiovascular MedicinebusinessLung TransplantationCohort studyThe Journal of Heart and Lung Transplantation
researchProduct

Universal Versus Culture-Directed Pre-Emptive Treatment (CDPET) among Lung Transplant Recipients: A Propensity-Score Matched Analysis

2016

Pulmonary and Respiratory MedicineTransplantationmedicine.medical_specialtyLungmedicine.anatomical_structurebusiness.industryInternal medicinePropensity score matchingMedicineSurgeryCardiology and Cardiovascular MedicinebusinessPre emptive treatmentThe Journal of Heart and Lung Transplantation
researchProduct

AISF position paper on HCV in immunocompromised patients.

2018

Abstract This report summarizes the clinical features and the indications for treating HCV infection in immunocompromised and transplanted patients in the Direct Acting Antiviral drugs era.

medicine.medical_specialtyTransplant RecipientComorbidityAntiviral AgentsOrgan transplantation03 medical and health sciencesImmunocompromised Host0302 clinical medicineInternal medicineNeoplasmsmedicineImmunocompromised patientHumansChronicIntensive care medicineAntiviral AgentHepatologybusiness.industryGastroenterologyHepatologyHepatitis C Chronicmedicine.diseaseComorbidityHepatitis COrgan transplantHCV; Immunocompromised patients; Organ transplant; Hepatology; GastroenterologyTransplant RecipientsHCV; Immunocompromised patients; Organ transplant; Antiviral Agents; Comorbidity; Hepatitis C Chronic; Humans; Immunocompetence; Italy; Neoplasms; Transplant Recipients; Immunocompromised HostItaly030220 oncology & carcinogenesisHCVHCV Immunocompromised patients Organ transplantPosition paperNeoplasmImmunocompromised patients030211 gastroenterology & hepatologyImmunocompetencebusinessImmunocompetenceDirect actingHumanDigestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
researchProduct

Clinical risk factors for invasive aspergillosis in lung transplant recipients: Results of an international cohort study

2018

BACKGROUND: Invasive aspergillosis (IA) is a frequent complication in lung transplant recipients (LTRs). Clinical risk factors for IA have not been fully characterized, especially in the era of extensive anti-fungal prophylaxis. The primary objective of this study was to evaluate the clinical risk factors associated with IA in LTRs. The secondary objective was to assess the mortality in LTRs who had at least 1 episode of IA compared with LTRs who never had experienced IA.METHODS: We conducted an international, multicenter, retrospective cohort study of 900 consecutive adults who received lung transplants between 2005 and 2008 with 4years of follow-up. Risk factors associated with IA were id…

Male0301 basic medicineAntifungal Agentsviruses030230 surgeryAspergillosisanti-fungal prophylaxis; Aspergillus spp; invasive aspergillosis; lung transplant recipient; single-lung transplant; Surgery; Pulmonary and Respiratory Medicine; Cardiology and Cardiovascular Medicine; TransplantationCohort StudiesPostoperative Complications0302 clinical medicineRisk Factorshemic and lymphatic diseasesMedicineInvasive Pulmonary AspergillosisFirst episodeMortality rateHazard ratioMiddle Agedembryonic structuresFemaleCardiology and Cardiovascular MedicineLung TransplantationCohort studyAdultPulmonary and Respiratory Medicinemedicine.medical_specialtyanimal structuresAdolescent030106 microbiologyYoung Adult03 medical and health sciencesanti-fungal prophylaxisInternal medicineHumansIntensive care medicineAgedProportional Hazards ModelsRetrospective Studiesinvasive aspergillosisTransplantationbusiness.industryProportional hazards modelAspergillus fumigatusAspergillus spp anti-fungal prophylaxis invasive aspergillosis lung transplant recipient single-lung transplantAspergillus sppRetrospective cohort studybiochemical phenomena metabolism and nutritionmedicine.diseaseSurvival Analysissingle-lung transplantTransplantationSurgerybusinesslung transplant recipientFollow-Up StudiesThe Journal of Heart and Lung Transplantation
researchProduct

Therapeutic strategies for severe COVID-19: a position paper from the Italian Society of Infectious and Tropical Diseases (SIMIT)

2021

Abstract Scope Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has become pandemic, reaching almost one million death worldwide. At present standard treatment for coronavirus disease 2019 (COVID-19) is not well defined because the evidence, either from randomized or observational studies, with conflicting results, has led to rapid changes in treatment guidelines. Our aim was to narratively summarize the available literature on the management of COVID-19 in order to combine current evidence and interpretation of the data by experts who are treating patients in the frontline setting. Methods The panel conducted a detailed review of the literature and eventual press rele…

0301 basic medicineMicrobiology (medical)medicine.medical_specialtyCoronavirus disease 2019 (COVID-19)030106 microbiologyCoronavirupractice guidelines as topiccoronavirusrandomized controlled trials as topicGuidelinesmedicine.disease_causemedicallaw.invention03 medical and health sciences0302 clinical medicinesocietiesRandomized controlled triallawPandemicitalymedicinepneumonia030212 general & internal medicineIntensive care medicinehumansSocieties MedicalCoronavirustherapySARS-CoV-2business.industryCOVID-19; Coronavirus; Pneumonia; SARS-CoV-2; TherapyStandard treatmentCOVID-19PneumoniaGeneral Medicinecovid-19; coronavirus; pneumonia; sars-cov-2; therapy; covid-19; humans; italy; randomized controlled trials as topic; sars-cov-2; societies medical; standard of care; practice guidelines as topicCOVID-19 Drug TreatmentCoronavirusClinical trialsars-cov-2Infectious Diseasescovid-19standard of carePosition paperObservational studyTherapyCoronavirus; COVID-19; Pneumonia; SARS-CoV-2; TherapybusinessHuman
researchProduct